TY - JOUR
T1 - An International Multicenter Comparison of IBD-Related Disability and Validation of the IBDDI
AU - Shafer, Leigh Anne
AU - Sofia, M. Anthony
AU - Rubin, David T.
AU - Steinhart, A. Hillary
AU - Ng, Siew C.
AU - Reches, Liran
AU - Israeli, Eran
AU - Bernstein, Charles N.
N1 - Funding Information:
Conflicts of Interest These authors disclose the following: David T. Rubin has received research funding from Takeda and has served as a consultant to AbbVie, Abgenomics, Allergan, Arena Pharmaceuticals, Biomica, Bristol-Myers Squibb, Dizal Pharmaceuticals, Ferring Pharmaceuticals, Genentech/Roche, Janssen Pharmaceuticals, Lilly, Mahana Therapeutics, Medtronic, Merck & Co., Napo Pharmaceuticals, Pfizer, Prometheus Laboratories, Shire, Takeda, and Target PharmaSolutions. A. Hillary Steinhart has received research funding from AbbVie, Arena Pharmaceuticals, Celgene, Genentech/Roche, Janssen, Nubiyota, and Takeda; served as a consultant or advisory board member for AbbVie, Janssen, Merck, Pfizer, Roche, and Takeda; and served on the speakers’ bureau for AbbVie, Pfizer, and Takeda. Siew C. Ng has received speakers’ fees from AbbVie, Ferring, Janssen, Pfizer, Menarini, Takeda, and Tillots; and research grants from AbbVie and Ferring. Charles N. Bernstein has served as a consultant for AbbVie Canada, Janssen Canada, Pfizer Canada, Shire Canada, and Takeda Canada; received unrestricted educational grants from AbbVie Canada, Janssen Canada, Pfizer Canada, Shire Canada, and Takeda Canada; served on the speakers’ bureau of AbbVie Canada, Janssen Canada, Medtronic Canada, and Takeda Canada; and received a research grant from AbbVie Canada and contract grants from AbbVie, Janssen, Pfizer, Celgene, Roche, and Boehringer Ingelheim. The remaining authors disclose no conflicts.
Publisher Copyright:
© 2021 AGA Institute
PY - 2021/12
Y1 - 2021/12
N2 - Background: The IBD disability index (IBDDI) has been shown to be valid and reliable. We compared the distributional and predictive properties of the IBDDI, when collected from five populations of people living with IBD– from Winnipeg, Chicago, Toronto, Hong Kong, and Jerusalem. Methods: People with IBD from five jurisdictions were invited to complete a survey including the IBDDI, the World Health Organization Disability Assessment Scale, the Work and Social Adjustment Scale, the IBDQ, the Kessler-6 distress scale, and the Stanford presenteeism scale. Between sites, we compared the correlation between IBDDI and the other 4 measures of disability/quality of life/distress, and the association between IBDDI and presenteeism and having been hospitalized in the past year. Results: There were 1121 participants from Winnipeg, 511 from Chicago, 147 from Toronto, 97 from Hong Kong, and 96 from Jerusalem. The majority had Crohn's disease. Although the mean IBDDI score varied by site, the correlation between IBDDI and each of the other 4 measures of disability/QOL/distress was nearly identical. Similarly, the regression coefficient showing the association between IBDDI and presenteeism was nearly identical in all sites, and the risk ratios showing the association between hospitalization and high IBDDI was similar in all sites. Conclusion: The correlation between IBDDI and different measures of disability/QOL/distress was similar across all sites. There is strong evidence of the association between IBD-related disability and presenteeism, and between hospitalization and high IBD-related disability, and that the associations are the same across different populations. The severity of disability that an individual with a given IBDDI score has is directly comparable across populations.
AB - Background: The IBD disability index (IBDDI) has been shown to be valid and reliable. We compared the distributional and predictive properties of the IBDDI, when collected from five populations of people living with IBD– from Winnipeg, Chicago, Toronto, Hong Kong, and Jerusalem. Methods: People with IBD from five jurisdictions were invited to complete a survey including the IBDDI, the World Health Organization Disability Assessment Scale, the Work and Social Adjustment Scale, the IBDQ, the Kessler-6 distress scale, and the Stanford presenteeism scale. Between sites, we compared the correlation between IBDDI and the other 4 measures of disability/quality of life/distress, and the association between IBDDI and presenteeism and having been hospitalized in the past year. Results: There were 1121 participants from Winnipeg, 511 from Chicago, 147 from Toronto, 97 from Hong Kong, and 96 from Jerusalem. The majority had Crohn's disease. Although the mean IBDDI score varied by site, the correlation between IBDDI and each of the other 4 measures of disability/QOL/distress was nearly identical. Similarly, the regression coefficient showing the association between IBDDI and presenteeism was nearly identical in all sites, and the risk ratios showing the association between hospitalization and high IBDDI was similar in all sites. Conclusion: The correlation between IBDDI and different measures of disability/QOL/distress was similar across all sites. There is strong evidence of the association between IBD-related disability and presenteeism, and between hospitalization and high IBD-related disability, and that the associations are the same across different populations. The severity of disability that an individual with a given IBDDI score has is directly comparable across populations.
KW - Disability
KW - Survey
KW - inflammatory bowel disease
KW - presenteeism
KW - quality of life
UR - http://www.scopus.com/inward/record.url?scp=85097202697&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85097202697&partnerID=8YFLogxK
U2 - 10.1016/j.cgh.2020.08.053
DO - 10.1016/j.cgh.2020.08.053
M3 - Article
C2 - 32858200
AN - SCOPUS:85097202697
SN - 1542-3565
VL - 19
SP - 2524
EP - 2531
JO - Clinical Gastroenterology and Hepatology
JF - Clinical Gastroenterology and Hepatology
IS - 12
ER -